<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02137863</url>
  </required_header>
  <id_info>
    <org_study_id>2011/345</org_study_id>
    <nct_id>NCT02137863</nct_id>
  </id_info>
  <brief_title>Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy</brief_title>
  <official_title>Phase 4 Study of Dexmedetomidine Effects on Preventing Contrast Induced Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TC Erciyes University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TC Erciyes University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to evaluate the effects of dexmedetomidine on renal function,
      hormonal and hemodynamic parameters in contrast media induced diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Contrast nephropathy may occur after using intravenous contrast media and may result in acute
      renal failure. Contrast nephropathy usually reversible but in some cases it can be permanent.
      This situation increase the time of hospitalization and mortality of the patients. Although
      the only proved prevention from contrast nephropathy method is hydration, infusion of
      dexmedetomidine may keep the renal functions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in glomerular renal function after percutaneous coronary angiography as measured by neutrophil gelatinase-associated lipocalin, cystatin c, blood urea nitrogen, creatinin</measure>
    <time_frame>1 day (from start of angioplasty till discharge from the hospital)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>1 day (from start of angiography till discharge from the hospital)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>1 day (from start of angiography till discharge from the hospital)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood electrolyte levels ( sodium, potassium, chloride)</measure>
    <time_frame>before the angiography and just before the discharge from hospital</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complete blood count</measure>
    <time_frame>before the angiography and just before the discharge from hospital</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Radiographic Contrast Agent Nephropathy</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.
During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.
100 ml/10min 0.9 % NaCl administered intravenously just before the angiography.
1 ml/kg/h 0.9 % sodium chloride administered intravenously during the procedure and was continued 1 hour after the angiography.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Before the angiography 0.9 % sodium chloride 3 ml/kg/h administered for 12 hours.
During the angiography and 12 hours after angiography 1 ml/kg/h 0.9 % sodium chloride administered.
Dexmedetomidine was diluted as 1 μg/ml. 1 μg/kg/10min dexmedetomidine administered intravenously just before the angiography.
1 μg/kg/h dexmedetomidine administered intravenously during the procedure and was continued 1 hour after the angiography.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Intravenously 1μg/kg/10min administered just before the procedure.
1 μg/kg/h administered during the angiography and was continued 1 hour after the angiography.</description>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9 % NaCl</intervention_name>
    <description>During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Dexmedetomidine</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9 % NaCl</intervention_name>
    <description>100 ml/10min infusion just before the angiography
1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Scheduled for percutaneous coronary angiography

          -  &gt; 18 yo

          -  Diabetic patients

          -  Creatinin value &lt; 3 mg/dl

        Exclusion Criteria:

          -  Contrast agent hypersensitivity

          -  Pregnant patients

          -  Creatinin value ≥3mg/dl

          -  patients have acute renal failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aynur Akın, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>TC Erciyes University</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2014</study_first_posted>
  <last_update_submitted>May 13, 2014</last_update_submitted>
  <last_update_submitted_qc>May 13, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>TC Erciyes University</investigator_affiliation>
    <investigator_full_name>Aynur Akın</investigator_full_name>
    <investigator_title>Prof Dr</investigator_title>
  </responsible_party>
  <keyword>Contrast induced nephropathy</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Dexmedetomidine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

